- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1742 |
Product Name |
ADT1742-Human Anti-Her2xHer3 Bispecific Antibody |
Isotype |
Human IgG1(K214R/L351K/T366K//K214R/L351D/L368E)-Kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-Her2 mAb, Anti-Her2 Monoclonal Antibody, Her2 recombinant antibody, Anti-Her2 Monoclonal Antibody, Anti-Her2 Bispecific Antibody, Human Anti-Her3 mAb, Her3 recombinant antibody, Anti-Her3 Monoclonal Antibody, Anti-Her3 Bispecific Antibody |
|
Official Symbol |
Her2xHer3 |
Target 1 |
Her2 |
Gene ID 1 |
2064 |
Target 2 |
Her3 |
Gene ID 2 |
2065 |
Species |
Human |
Drug Name |
Zenocutuzumab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
1969309-56-5 |
Chemical Formula |
C6479H9971N1725O2027S45 |
Molecular Weight |
146 KDa |
Product Description |
Zenocutuzumab is a HER2xHER3 bispecific antibody used to treat non-small cell lung cancer and pancreatic adenocarcinoma in adults with a NRG1 gene fusion.
|
Mechanism of Action |
Zenocutuzumab is a bispecific antibody with two different Fab arms that each binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells. Neuregulin 1 (NRG1) is a growth factor characterized by an epidermal growth factor (EGF)-like domain, which facilitates binding with various protein kinases, including receptor tyrosine-protein kinase erbB-2 (ERBB2/HER2) and ERBB3 (HER3). These interactions lead to heterodimerization or oligomerization with other ERBB family members, activating downstream signaling pathways that drive cell growth. Notably, the HER2–HER3 dimer is regarded as the most oncogenic heterodimer within the ERBB family.1 NRG1 gene fusions act as oncogenic drivers and have been linked to cancers such as non-small-cell lung cancer (NSCLC) and pancreatic cancer. These fusions result in structural DNA alterations and deregulated cell proliferation. |
Metabolism |
Zenocutuzumab is expected to be metabolized into small peptides by catabolic pathways. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
The product need to be stored at the original stock concentration at 4°C. Avoid freeze/thaw cycle. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, Wasserman E, de Stanchina E, O'Reilly EM, Ladanyi M, Drilon A, Somwar R: Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247. doi: 10.1158/2159-8290.CD-21-1119.
2. Fontana E, Torga G, Fostea R, Cleator S, Wasserman E, Murat A, Arkenau HT: Sustained 2. Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor. JCO Precis Oncol. 2022 Aug;6:e2100446. doi: 10.1200/PO.21.00446.
|
FAQ
-
+ -
What are HER2 and HER3?
HER2 (ERBB2) and HER3 (ERBB3) are receptor tyrosine kinases in the EGFR family. HER2 overexpression drives cancer growth, while HER3 mediates resistance to HER2-targeted therapies.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
What are bispecific antibodies (BsAbs)?
Bispecific antibodies (BsAbs) are antibodies with two binding sites targeting two different antigens or two different epitopes on the same antigen. -
+ -
How does this bispecific antibody work?
It simultaneously blocks HER2 and HER3 signaling, preventing tumor growth and overcoming resistance mechanisms.